CURRICULUM VITAE

Douglas Reid Patterson, D.V.M., Ph.D.
Diplomate: A.B.T., A.C.V.P., A.C.L.A.M.; Fellow: A.T.S., I.A.T.P.

CURRENT POSITION: **President, Reid Patterson Consulting, Inc.**
Email: reidpattersonconsulting@comcast.net, rpc-inc@comcast.net,
or reidpatterson@comcast.net
Cell: 239-398-6739
Website: www.reidpattersonconsulting.com
23620 Waterside Drive (Main & Winter Office 10/15-5/15)
Bronita Springs, FL 34134-4905
Phone: 239-676-9371
W5210 Plantation Road (Summer Office 5/15-10/15)
Elkhorn, WI 53121-3120
Phone: 262-742-4998

EDUCATION: **Bachelor of Science (B.S.),** Texas A&M University, l968

Doctor of Veterinary Medicine (D.V.M.), Texas A&M U., l969

Residency in Laboratory Animal Medicine, U. Mo., 1971-5

Doctor of Philosophy (Ph.D.), U. of Missouri, l976

30 hours toward M.B.A. (U. Houston & Northern Illinois)

SPECIALTY CERTIFICATION: **Diplomate, American College of Laboratory Animal Medicine**, l976

Diplomate, American College of Veterinary Pathologists, l978

Diplomate, American Board of Toxicology, l98l

SPECIALTY RECOGNITION: **Fellow, Academy of Toxicological Sciences**, 2000

Fellow, International Academy of Toxicologic Pathology, 2001

PROFESSIONAL EXPERIENCE:

President, Reid Patterson Consulting, Inc.	(2003-present)
Divisional Vice President, Global Preclinical Safety, Abbott Laboratories	(2001-2003)
Divisional Vice President, Drug Safety Evaluation, Abbott Laboratories	(1991-2001)
Head, Neuroscience Venture, Abbott Laboratories	(1992-93)
Director, Division of Drug Safety Evaluation, Abbott Laboratories	(1987-90)
Director, Pathology/Toxicology, Abbott Laboratories	(1984-87)
Supervisor, Pathology, Teratology & Repro. Tox., Shell Development Co.	(1981-84)
Director, Department of Medicine, Hazleton Labs. America	(1980-81)
Head, Department of Pathology, Hazleton Labs. Europe	(1978-80)
Pathologist, Department of Pathology, Hazleton Labs. America	(1975-78)
Post-Doc. Fellow, Dept. Lab. Animal Med., U. Mo. Med. School	(1971-75)
Practitioner, Veterinary clinical practice, Houston, TX	(1969-71)

[D. Reid Patterson, D.V.M., Ph.D.]

DETAILED PROFESSIONAL EXPERIENCE: PHARMACEUTICAL INDUSTRY

President, Reid Patterson Consulting, Inc.,
Pharmaceutical R&D consulting firm, Grayslake, IL 60030; Present Position (Jan. 2004 to present)

Dr. Patterson elected to utilize his 40+ years of professional veterinary life, 35+ years as a toxicologic pathologist, 20 years as a pharmaceutical research and development (R&D) executive, and 12 years as a drug development consultant to assist and advise pharmaceutical and biotechnology firms in the successful development of therapeutics vital to society's needs. During Dr. Patterson's tenure at Abbott Laboratories, he participated in the development of drugs for acid reflux, AIDs, analgesia, anemia, anesthesia, asthma, benight prostatic hyperplasia and cancer, bipolar disorder, cancer, cardiovascular disorders, diabetes, depression, epilepsy, erectile dysfunction, fungal diseases, gastric motility, hepatic disease, hormone replacement therapy, immunosuppression, infectious disease, iron deficiency, lupus erythematosis, migrane headaches, obesity, pain management, pulmonary function, renal failure, rheumatoid arthritis, schitzophrenia, sedation, stents, surgical suturing, thromobses, urinary incontinence, viral diseases, and others. The targets have expanded during his consulting experience. He uses these experiences to assist firms in strategic planning, development program design, study design, placement and monitoring and in the assembly of scientific data into coherent submissions to global regulatory agencies. To date, Dr. Patterson supports over 50 pharmaceutical clients and makes regular presentations on their behalf.

Divisional Vice President, Global Preclinical Safety
Global Pharmaceutical R&D Division, Abbott Laboratories, Abbott Park, IL 60064-3500; Previous Position: (Jan. 2001- Dec. 2003)

Dr. Patterson had managerial and scientific responsibilities for the safety assessment of all drug candidates and other potential in vivo Abbott products throughout the world, plus provided research support in the drug discovery process. To accomplish these tasks, a team of multidiciplinary scientists generated data and reports describing drug absorption, distribution, metabolism, and excretion (ADME) in subhuman and human subjects and patients plus any associated toxicologic pathology in representative animal models. Ultrastructural and biochemical characterization of products and tissues through the use of electron microsocopy and cellular biological techniques was under his authority. The departments essential in these efforts included Experimental Kinetics and Analysis; Regulatory Toxicology & Safety Pharmacology; Pathology; Clinical Pathology; Comparative Medicine; Drug Analysis; Metabolism, Radiochemistry & Cellular Toxicity; and Cellular & Microscopic Research. The organization was composed of approximately 250 scientific personnel, including about 50 doctoral-level professionals under a budget of over $70MM.

Dr. Patterson planed, organized, and directed the uses of manpower, facilities, materials, equipment and budgets of this division and its departments. He formulated departmental and divisional goals in light of corporate and divisional objectives, implemented divisional and corporate policies, assigned duties and functions and measured performance in terms of goals and commitments.

Technical and administrative decisions, recommendations, and leadership were the responsibility of the Vice President. Problem solving of personnel, administrative and budgetary issues were his responsibility. The design, conduct, evaluation, interpretation and reporting of all safety assessments studies in a timely and cost-effective manner were critical to the Division's success. The Vice President served as a key resource in the presentation and scientific discussion of all safety (toxicity), metabolic and chemical data on potential and existing products to domestic and foreign regulatory bodies.

Dr. Patterson acted as a resource on matters pertaining to personnel safety and serves on numerous corporate and divisional committees and task forces involved with issues vital to or of interest to the corporation, including his role as the Institutional Official and former Chairman of Abbott's Institutional Animal Care and Use Committee. The Vice President reported directly to a manager from the former Knoll organization, the Divisional Vice-President for Global Preclinical Drug Development of the Global Pharmaceutical R&D Division of Abbott Laboratories.

[D. Reid Patterson, D.V.M., Ph.D.]

Divisional Vice President, Drug Safety Evaluation
GPRD, Abbott Laboratories, Abbott Park, IL 60064-6104
Previous Position: (Jan. 1991-Jan. 2001)

Dr. Patterson had the same responsibilities described above with the exception of 37 staff members in Germany obtained during the acquisition of Knoll (BASF) Pharmaceuticals. In 1995, Drug Safety Evaluation was comprised of approximately 400 scientific personnel, including over 120 doctoral-level scientists and an operating and capital budget of approximately $71MM. Up until November, 1995, the responsibility additionally included the Division of Analytical Research, comprised of the Departments of Structural Chemistry, Physical Analytical Chemistry, Bioanalytical Chemistry, Anti-Infective Analytical Research, and Protein Chemistry. This organization provided data on the chemical characterization, stability, and analytical methodologies for every new drug entity and is currently organized under a different Divisional VP for Pharmaceutical Analytical and Research Development. Up until December, 1999, his responsibility included Clinical Pharmacokinetics, a staff of approximately 20 scientists; this organization was then merged with Clinical Pharmacology to create a new Division. In 2001, a Cellular and Molecular Toxicology team formed and trained in DSE was moved into the Discovery organization to be more directly supported and funded by their clients. Dr. Patterson reported to a Corporate Vice President for Research & Development, then later to a newly appointed Corporate Vice President for Development, during these 10 years.

Head, Neurotherapeutics Venture
PPD, Abbott Laboratories, Abbott Park, IL 60064-3500
Previous Position: (Aug., 1992 - Nov. 1993)

Dr. Patterson had responsibility for the rapid and safe development of tiagabine hydrochloride, a novel anti-epileptic agent intended for the treatment of patients with partial seizures, including those with complex symptomatology with or without secondary generalized tonic-clonic seizures. Responsibilities included the creation of strategic plans, hiring key staff of the venture team, directing all activities from chemical production of bulk drug to performance of clinical trials, managing the financial resources, providing safe and ethical oversight, motivating and leading supporting technical specialists, and assuring regulatory compliance and understanding. With a professional staff of approximately 30 (4 doctoral level) and numerous contracted external professionals, Dr. Patterson managed the $20 million/annum program successfully from Phase II into Phase III and through the End-of-Phase II meeting with the FDA. He further had responsibility for and directed an extended team of supporting professionals in bulk drug synthesis, analytical research, formulation, metabolism, pharmacology, pharmacokinetics, toxicology, data management, statistics and numerous clinical support groups, including an external CRO. The position reported intially to the Vice President for Development, Pharmaceutical Products Division of Abbott Laboratories, but later reported into a Vice President for Immunoscience, Neuroscience, Cardiovascular and Thrombolytic Development. (This position was held concurrently with responsibilities as Vice President for Drug Safety Evaluation, with a combined responsibility for nearly 400 professional and technical staff and approximately $75MM in budget responsibility.)

Director, Division of Drug Safety Evaluation
PPD, Abbott Laboratories, Abbott Park, IL
Previous Position: (July, l987 - Dec., 1990)

Dr. Patterson's former responsibilities were similar to those mentioned above under DVP, DSE, except the scope of the responsibilities was somewhat less. His former position was expanded in 1987 to incorporate the Departments of Analytical Research, Drug Metabolism and Cellular and Microscopic Research (formerly known as Electron Microscopy). Thus, he began with a staff of 177 members and a budget of just under $20MM.

[D. Reid Patterson, D.V.M., Ph.D.]

Director, Pathology/Toxicology
PPD, Abbott Laboratories, Abbott Park, IL
Previous Position: (July, 1984 - July, 1987)

In his initial position with Abbott, Dr. Patterson was responsible for the safety assessment of drug candidates and other potential Abbott products by the proper conductance and interpretation of animal safety and mutagenicity studies. The departments essential in these efforts were Toxicology, Pathology and Animal Health and Services, represented by over 75 scientific personnel and an operating budget of approximately $7MM. His general responsibilities were those described in his later positions, albeit without the chemistry and research arms currently within the Division.

DETAILED PROFESSIONAL EXPERIENCE: PETROCHEMICAL INDUSTRY

Supervisor - Pathology, Teratology and Reproductive Toxicology
Department of Pathobiology, Toxicology Laboratory, Westhollow
Research Center, Shell Development Company, Houston, Texas.
Previous Position: (April, l98l - July, l984)

Dr. Patterson's primary responsibilities related to laboratory operations management with particular emphasis on the development and administration of clinical and anatomic pathology services and the research efforts in teratology and reproductive toxicology at the Westhollow Research Center. He also supervised research and technical services provided to petroleum product business areas of the company and administered Toxicology's interaction in the American Petroleum Institute.

Specific tasks included interpreting morphological responses to toxic injury in experimental animals to other scientists in Shell and at regulatory agencies and to business managers, designing, monitoring and reviewing toxicology studies, coordinating the workload within the clinical and anatomic pathology laboratories and between other laboratory groups, establishing and maintaining functional relationships with other laboratory groups and business centers, reviewing and approving study plans, reviewing protocols and reports, and assuring the timing and quality of the laboratory work in all areas of pathology and reproductive toxicology.

He also had responsibility for the development and maintenance of standard laboratory operating procedure manuals, performance appraisals of professional and support staff, staff training and related documentation and maintenance of necessary skill levels and facilities within his group. Budgetary development and cost control were also within his charge. Finally, he was responsible for the maintenance of trained personnel knowledgeable in areas of pathology pertinent to Shell products and in the technical contribution of this knowledge and experience.

Dr. Patterson also provided technical support to the Animal Resources group because of his co-specialization in laboratory animal medicine. He held an academic appointment as an adjunct Assistant Professor within the Department of Comparative Medicine, University of Texas Medical School at Houston until his departure from Texas in l984.

DETAILED PROFESSIONAL EXPERIENCE: CONTRACT LABORATORY INDUSTRY

Director, Department of Medicine
Hazleton Laboratories America, Inc., Vienna, VA.
Previous Position: (July, l980 - March, l98l)

Dr. Patterson was principally responsible for the development and implementation of policies insuring the humane care and management of the numerous laboratory animal species used at Hazleton. Compliance with the Animal Welfare Act and its amendments, plus the Guide for the Care and Use of Laboratory Animals, produced by D.H.E.W. and implemented by A.A.A.L.A.C., was a major responsibility of the Department of Medicine and Hazleton's Animal Care Committee, both chaired by Dr. Patterson.

[D. Reid Patterson, D.V.M., Ph.D.]

Duties relating to laboratory animal care for which Dr. Patterson was responsible, included the development of company policies and standard procedures for animal handling and experimental use, monitoring and evaluating the animals' macro- and microenvironment for microbiological and chemical contaminants, assuring compliance with guidelines established by N.I.H., F.D.A., E.P.A. and A.A.A.L.A.C., approving all facility renovations and designs relating to animal care, evaluating animal, feed and bedding suppliers, certifying health status of experimental animals and selecting appropriate laboratory equipment.

Dr. Patterson was also responsible for sampling and interpreting the contaminant analyses of food, water and bedding, coordinating a vermin control program, providing clinical services in ophthalmology, cardiology, neurology and radiology and developing and administering technician training programs. To accomplish these tasks, Dr. Patterson had both professional (D.V.M.) and technical staff in his department.

As Director of the Department of Medicine, Dr. Patterson also supervised the Microbiology Laboratory, which provided support for internal studies, laboratory animal medicine, and external clients. Dr. Patterson principally worked with the Head of the Laboratory in areas of fiscal accountability, program development, marketing and personnel relations.

Being a pathologist and scientist, Dr. Patterson had continued his involvement in histopathology and project management by participating in studies at Hazleton and by establishing a referral contract pathology service for external clients. Dr. Patterson was developing a new laboratory animal diagnostic service for animal producer and user laboratories.

Head, Department of Pathology
Hazleton Laboratories Europe Ltd., Harrogate, England.
Previous Position: (June, l978 - July, l980)

Dr. Patterson was singly responsible for the development and supervision of the Department of Pathology and for the coordination with other departments within the laboratories. These duties included scheduling, monitoring and performing or supervising the histopathologic interpretation of tissues from experiments using all the common laboratory animal species. Dr. Patterson was responsible for the procurement of new equipment, the review of experimental protocols, the training of new staff, the assurance of quality data, the authorship and updating of procedure manuals, plus the development and monitoring of annual budgets. Before being recalled to the American laboratories, Dr. Patterson hired 5 additional pathologists and established a contract pathology service, principally serving continental European clients.

Dr. Patterson also served as principal investigator of several toxicology studies, provided needed interpretation of clinical pathology data in many other experiments and supervised the Head of Laboratory Animal Medicine. During his tenure, Dr. Patterson was successful in establishing a U.K./European Division of the Charles Louis Davis, D.V.M. Foundation for the Advancement of Veterinary Pathology, an American organization providing continuing education to veterinary, experimental and research pathologists.

Staff/Senior Staff Pathologist
Department of Pathology, Hazleton Laboratories America, Inc.,
Vienna, VA. Previous Position: (Sept., l975 - June, l978)

Dr. Patterson's principal responsibility was to provide macroscopic and microscopic description and interpretation of spontaneously occurring and experimentally induced pathological lesions in numerous laboratory animal species. In performing these duties, he compiled the data into incidence tables and interpreted their relationship to the experimental protocol. He also supervised necropsy procedures to insure proper description of gross observations, utilization of tissue preservatives, and handling and collection of required tissues.

Dr. Patterson also participated as co- or principal investigator on experimental projects and in doing so was actively involved in the review of pertinent literature, experimental design, experiment implementation and data evaluation. He was actively involved in the clinical and pathological evaluation of the laboratory animals in support of the Director of Laboratory Animal Medicine. He taught portions of several courses in laboratory animal medicine and clinical pathology at Hazleton and in an area college.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.